Clinical trials
Triple Negative Breast Neoplasms trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
71 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 7 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 11 |
| 2026 | 15 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 26 |
| Active, not recruiting | 11 |
| Not yet recruiting | 9 |
| Withdrawn | 9 |
| Completed | 9 |
| Unknown status | 4 |
| Terminated | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institut Curie | 5 |
| M.D. Anderson Cancer Center | 4 |
| City of Hope Medical Center | 3 |
| Ohio State University Comprehensive Cancer Center | 3 |
| University of Southern California | 3 |
| European Institute of Oncology | 2 |
| Samsung Medical Center | 2 |
| Sunnybrook Health Sciences Centre | 2 |
| UNICANCER | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 71 |
| Breast Neoplasms | 33 |
| Ovarian Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Recurrence | 3 |
| Vulvar Neoplasms | 3 |
| Brain Neoplasms | 2 |
| Carcinoma, Renal Cell | 2 |
| Colonic Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
Trials
Showing 51 to 71 of 71. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.